KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Assets (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Non-Current Assets for 8 consecutive years, with $217.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 27.11% to $217.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $771.1 million through Dec 2025, up 15.0% year-over-year, with the annual reading at $217.5 million for FY2025, 27.11% up from the prior year.
  • Non-Current Assets hit $217.5 million in Q4 2025 for Castle Biosciences, up from $205.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $217.5 million in Q4 2025 to a low of $10.7 million in Q1 2021.
  • Historically, Non-Current Assets has averaged $142.5 million across 5 years, with a median of $156.4 million in 2023.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 1018.03% in 2021 and later dropped 6.39% in 2025.
  • Year by year, Non-Current Assets stood at $108.8 million in 2021, then surged by 42.46% to $155.0 million in 2022, then increased by 1.72% to $157.7 million in 2023, then rose by 8.48% to $171.1 million in 2024, then rose by 27.11% to $217.5 million in 2025.
  • Business Quant data shows Non-Current Assets for CSTL at $217.5 million in Q4 2025, $205.2 million in Q3 2025, and $196.1 million in Q2 2025.